Treatment of Parkinson's disease: use of piribedil
Gekht, A.B.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 104(1): 54-56
2004
ISSN/ISBN: 1997-7298 PMID: 14870695 Document Number: 573876
Document emailed within 1 workday
Related Documents
Sweet, R.D.; Wasterlain, C.; McDowell, F.H. 1974: Piribedil--an oral dopamine agonist for treatment of Parkinson's disease Transactions of the American Neurological Association 99: 258-260Suwantamee, J.; Nidhinandana, S.; Srisuwananukorn, S.; Laptikultham, S.; Pisarnpong, A.; Chankrachang, S.; Bundhukul, A. 2004: Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study Journal of the Medical Association of Thailand 87(11): 1293-1300
Ziégler, M.; Rondot, P. 1999: Action of piribedil in Parkinson disease. Multicenter study Presse Medicale 28(26): 1414-1418
Jiménez Jiménez, F.J.; Ladero Quesada, J.M. 1990: An experimental model of Parkinson disease caused by a neurotoxin: implications in the clinical aspects and the etiology of Parkinson disease Medicina Clinica 94(15): 585-595
Tanasanvimon, S.; Ayuthaya, N.I.N.; Phanthumchinda, K. 2007: Modified Parkinson's Disease Sleep Scale (MPDSS) in Thai Parkinson's disease patients Journal of the Medical Association of Thailand 90(11): 2277-2283
Hattori, N. 2004: Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease Rinsho Shinkeigaku 44(4-5): 241-262
Jankovic, J. 2001: Parkinson's disease therapy: treatment of early and late disease Chinese Medical Journal 114(3): 227-234
Sale, P.; De Pandis, M.F.; Vimercati, S.L.; Sova, I.; Foti, C.; Tenore, N.; Fini, M.; Stocchi, F.; Albertini, G.; Franceschini, M.; Galli, M. 2013: The relation between Parkinson's disease and ageing. Comparison of the gait patterns of young Parkinson's disease subjects with healthy elderly subjects European Journal of Physical and Rehabilitation Medicine 49(2): 161-167
Rasmussen, V.G.; Dupont, E.; Østergaard, K.; Egeblad, H. 2006: Valvular heart disease associated with the treatment of Parkinson disease Ugeskrift for Laeger 168(26-32): 2542-2544
Rabasseda, X. 1999: Perspectives in the treatment of Parkinson's disease: COMT inhibitors open up new treatment strategies Drugs of Today 35(9): 701-717
Vijayaraghavan, A.; Radhakrishnan, K. 1995: Treatment of Parkinson's disease Neurology India 43(2): 77-82
Jameson, H.D. 1972: Treatment of Parkinson's disease Journal of the Kentucky Medical Association 70(4): 304-307
Vijayaraghavan, A.; Radhakrishnan, K. 1996: Treatment of Parkinson's disease Neurology India 44(4): 177-182
Grieger, T.A.; Cozza, K.; Armstrong, S. 1994: Treatment of Parkinson's disease New England Journal of Medicine 330(9): 643-644
Jiménez-Jiménez, F.J. 1999: The treatment of Parkinson disease Medicina Clinica 112(7): 257-258
Bergus, G. 1996: Treatment of Parkinson's disease Journal of Family Practice 42(5): 457-458
Stefanache, F.; Pendefunda, G.H. 1990: Current treatment in Parkinson's disease Revista Medico-Chirurgicala a Societatii de Medici Si Naturalisti Din Iasi 94(2): 411-416
Dickerson, L.M.; Young, S.E.; Simpson, W.M.; Nashelsky, J. 2005: Treatment of early Parkinson's disease American Family Physician 72(3): 497-500
Derome, P.J.; Jedynak, C.P.; Visot, A.; Delalande, O. 1989: Stereotaxic treatment in Parkinson's disease La Revue du Praticien 39(8): 670-674
Lees, A.J. 1986: L-dopa treatment and Parkinson's disease Quarterly Journal of Medicine 59(230): 535-547